Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The cerebellum: a transdiagnostic personalised target for neuromodulation in psychiatry

Project description

Leveraging the cerebellum to treat resistant psychiatric symptoms

In addition to coordinating movement, the cerebellum also plays a role in how we think and feel. Even though it takes up only 10 % of the brain’s volume, it is packed with more than half of all our neurons. Many of these are wired into areas responsible for higher-order thought, making the cerebellum a prime target for non-invasive brain stimulation. The ERC-funded CLOVIS project aims to use this connection to treat symptoms of schizophrenia or bipolar disorder, especially those that do not respond well to standard medication. This project will use MRI models and direct brain recordings. Researchers will pinpoint exactly where and how to apply stimulation for best results. The goal is to move from lab theories to a clinical trial, proving that personalised brain stimulation can actually improve daily life for people with these conditions.

Objective

Have you ever had that moment where you reach for something, convinced it is heavy, but it is actually light? Your arm jolts upward, correcting itself before you realise the difference. This split second adjustment is thanks to your cerebellum, the part of your brain responsible for fine-tuning movements by integrating sensory feedback. While the cerebellum is traditionally associated with motor control, it plays a similar role in cognitive functions. Despite occupying 10% of the brain’s volume, the cerebellum houses more than 50% of its neurons, many of which are integral to higher cognitive processes. Its extensive connections with brain regions responsible for complex thought and emotion make it a promising target for non-invasive brain stimulation (NIBS) especially in addressing the resistant cognitive and negative symptoms observed in psychiatric disorders such as schizophrenia, bipolar disorder, and autism. However, a significant challenge persists: clinical research on NIBS often relies on a trial-and-error approach, while fundamental research has yet to fully translate electrophysiological findings into circuit-level applications that can guide clinical interventions. To bridge this gap, I will develop normative models from large-scale MRI cohorts to identify patients who are most likely to benefit from cerebellar stimulation and then derive a personalised cerebellar target. Concurrently, animal studies using ultra-high field MRI will be conducted to determine optimal cerebellar stimulation parameters. With intracranial recordings, I will explore the neuroplastic changes induced by NIBS in humans. The project will culminate in a proof-of-concept clinical trial aiming at improving cognitive and negative symptoms across schizophrenia, bipolar disorder and autism with cerebellar NIBS. This multidisciplinary project has the potential to revolutionize the treatment of resistant psychiatric symptoms and catalyse advancements in the understanding of NIBS.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

UNIVERSITE PARIS XII VAL DE MARNE
Net EU contribution
€ 1 085 000,00
Address
AVENUE DU GENERAL DE GAULLE 61
94010 Creteil
France
Region
Ile-de-France Ile-de-France Val-de-Marne
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 085 000,00

Beneficiaries (2)